Arcutis Biotherapeutics Inc (ARQT)

NASDAQ
23.18
-0.74(-3.09%)
  • Volume:
    204,116
  • Bid/Ask:
    22.25/24.50
  • Day's Range:
    22.78 - 24.13

ARQT News

Prev. Close
23.92
Day's Range
22.78-24.13
Revenue
-
Open
23.44
52 wk Range
17.51-38.49
EPS
-3.41
Volume
204,116
Market Cap
1.16B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
178,070
P/E Ratio
-
Beta
-
1-Year Change
-7.5%
Shares Outstanding
50,241,789
Next Earnings Date
Nov 11, 2021
What is your sentiment on Arcutis Biotherapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Arcutis Biotherapeutics Inc News

Arcutis Biotherapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellNeutralBuySell
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyStrong Sell
SummaryStrong SellStrong SellSellStrong BuyStrong Sell

Arcutis Biotherapeutics Inc Company Profile

Arcutis Biotherapeutics Inc Company Profile

Employees
54

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.